Gillian E Caughey1, Lisa M Kalisch Ellett2, John D Barratt2, Sepehr Shakib3. 1. Senior Research Fellow, Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471 Adelaide, South Australia 5001, Australia. 2. Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, Adelaide, Australia. 3. Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia.
Abstract
INTRODUCTION: Little is known about the potential safety issues associated with apixaban in clinical practice and their reporting in spontaneous adverse event (SAE) databases. OBJECTIVE: To describe SAE reports associated with the oral anticoagulant apixaban from Australia, Canada and USA and to examine associated concomitant medicine use. METHODS: SAE report databases from Australia, Canada and the USA were examined for all reports of adverse events associated with apixaban and concomitant medicines from 1 January 2012 to 30 September 2014. Disproportionality analysis (proportional reporting ratio (PRR) and reporting odds ratio (ROR)) was conducted for the quantitative detection of signals using the USA database. RESULTS: There were 97 SAE reports associated with apixaban from Australia, 77 from Canada and 2877 from the USA. Reporting of haemorrhage (any type) was common, ranging from 18% for USA to 31% for Australia. Gastrointestinal (GI) haemorrhage was the most commonly reported haemorrhage, accounting for approximately 10% of adverse event reports across all countries. Positive signals were confirmed in the USA data (haemorrhage (any type) PRR, 12.1; χ2, 5582.2 and ROR, 13.4; 95% CI: 12.13-14.6; GI haemorrhage PRR, 11.8; χ2, 2325.4 and ROR, 12.3; 95% CI, 10.8-14.0). Reporting of concomitant use of medicines with the potential to increase bleeding risk ranged from 47.6% in Canada to 65.5% in Australia. CONCLUSION: A large proportion of adverse event reports for apixaban were associated with use of concomitant medicines which may have increased the risk of haemorrhage.
INTRODUCTION: Little is known about the potential safety issues associated with apixaban in clinical practice and their reporting in spontaneous adverse event (SAE) databases. OBJECTIVE: To describe SAE reports associated with the oral anticoagulant apixaban from Australia, Canada and USA and to examine associated concomitant medicine use. METHODS:SAE report databases from Australia, Canada and the USA were examined for all reports of adverse events associated with apixaban and concomitant medicines from 1 January 2012 to 30 September 2014. Disproportionality analysis (proportional reporting ratio (PRR) and reporting odds ratio (ROR)) was conducted for the quantitative detection of signals using the USA database. RESULTS: There were 97 SAE reports associated with apixaban from Australia, 77 from Canada and 2877 from the USA. Reporting of haemorrhage (any type) was common, ranging from 18% for USA to 31% for Australia. Gastrointestinal (GI) haemorrhage was the most commonly reported haemorrhage, accounting for approximately 10% of adverse event reports across all countries. Positive signals were confirmed in the USA data (haemorrhage (any type) PRR, 12.1; χ2, 5582.2 and ROR, 13.4; 95% CI: 12.13-14.6; GIhaemorrhage PRR, 11.8; χ2, 2325.4 and ROR, 12.3; 95% CI, 10.8-14.0). Reporting of concomitant use of medicines with the potential to increase bleeding risk ranged from 47.6% in Canada to 65.5% in Australia. CONCLUSION: A large proportion of adverse event reports for apixaban were associated with use of concomitant medicines which may have increased the risk of haemorrhage.
Authors: Nicole L Pratt; Emmae N Ramsay; Gillian E Caughey; Sepehr Shakib; Elizabeth E Roughead Journal: Med J Aust Date: 2016-02-15 Impact factor: 7.738
Authors: Cameron J McDonald; Lisa M Kalisch Ellett; John D Barratt; Gillian E Caughey Journal: Pharmacoepidemiol Drug Saf Date: 2014-05-20 Impact factor: 2.890
Authors: Claes Held; Elaine M Hylek; John H Alexander; Michael Hanna; Renato D Lopes; Daniel M Wojdyla; Laine Thomas; Hussein Al-Khalidi; Marco Alings; Dennis Xavier; Jack Ansell; Shinya Goto; Witold Ruzyllo; Mårten Rosenqvist; Freek W A Verheugt; Jun Zhu; Christopher B Granger; Lars Wallentin Journal: Eur Heart J Date: 2014-12-12 Impact factor: 29.983
Authors: Elaine M Hylek; Claes Held; John H Alexander; Renato D Lopes; Raffaele De Caterina; Daniel M Wojdyla; Kurt Huber; Petr Jansky; Philippe Gabriel Steg; Michael Hanna; Laine Thomas; Lars Wallentin; Christopher B Granger Journal: J Am Coll Cardiol Date: 2014-03-19 Impact factor: 24.094
Authors: Daniel M Witt; Thomas Delate; David A Garcia; Nathan P Clark; Elaine M Hylek; Walter Ageno; Francesco Dentali; Mark A Crowther Journal: Arch Intern Med Date: 2012-10-22
Authors: Bruce L Davidson; Sara Verheijen; Anthonie W A Lensing; Martin Gebel; Timothy A Brighton; Roger M Lyons; Jeffrey Rehm; Martin H Prins Journal: JAMA Intern Med Date: 2014-06 Impact factor: 21.873
Authors: Markus Gulilat; Denise Keller; Bradley Linton; A Demetri Pananos; Daniel Lizotte; George K Dresser; Jeffrey Alfonsi; Rommel G Tirona; Richard B Kim; Ute I Schwarz Journal: J Thromb Thrombolysis Date: 2020-02 Impact factor: 2.300